Biogen Inc. has announced a significant investment of $2 billion in its manufacturing operations at North Carolina’s Research Triangle Park (RTP). This decision builds on the company’s 30-year presence in the region, where it has already invested around $10 billion.
The new funds will be used to enhance Biogen’s manufacturing capabilities across its two campuses in RTP. The expansion will focus on increasing antisense oligonucleotide capabilities and infrastructure, developing clinical and commercial multi-platform fill finish capabilities, and modernizing technologies with advanced automation and artificial intelligence.
Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen, expressed pride in the company’s ongoing commitment to innovation and collaboration within the RTP community. She stated that this investment would help modernize and expand their manufacturing capacity to support their pipeline while continuing to back North Carolina’s life sciences talent.
Biogen is recognized as North Carolina’s largest biotechnology employer, employing over 1,500 people along with more than 400 skilled contractors. More than 90% of Biogen’s innovator commercial medicines undergo manufacturing and quality control testing within the U.S., primarily at RTP.
Globally, Biogen operates with a strategy focused on ensuring high-quality patient supply through geographical risk diversification and dual sourcing. In addition to its facilities in North Carolina, Biogen maintains operations internationally with a biologics factory in Switzerland and consolidated fill finish capabilities in Ireland.
Founded in 1978, Biogen is known for pioneering innovative science aimed at delivering transformative medicines for patients worldwide. The company continues to balance bold risks with return on investment for sustained growth.
The press release includes forward-looking statements about potential benefits from investments in global manufacturing footprints but cautions about associated risks inherent in drug development and commercialization.
